CTOs on the Move


 
Curaleaf Holdings, Inc. is the leading vertically integrated multi-state cannabis operator in the United States.The company is positioned in highly populated, limited license states, and currently operates in 12 states with 44 dispensaries, 12 cultivation sites and 11 processing sites.
  • Number of Employees: 1K-5K
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Curaleaf raised $300M on 01/16/2020
Curaleaf raised $130M on 04/07/2021

Similar Companies

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company has advanced its lead candidate, resmetirom, also known as MGL-3196, a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist, through Phase 2 clinical trials in NASH. Primary and key secondary endpoints were achieved including reduction of liver fat on a sensitive non-invasive imaging test, lowering of multiple atherogenic lipids including LDL-cholesterol and triglycerides, and resolution of NASH on liver biopsy. Based on evidence of broad activity and a favorable safety profile, Madrigal has initiated a Phase 3 clinical study in NASH patients with advanced liver fibrosis, MAESTRO-NASH, in which the primary endpoint after one year of dosing is resolution of NASH and key secondary endpoints include LDL-cholesterol lowering and reduction in liver fibrosis. Clinical benefit in reducing progression to more advanced liver disease, including cirrhosis, is a long-term goal of this trial. A second Phase 3 clinical study, MAESTRO-NAFLD-1, has also been initiated. This 52-week non-invasive study in a broader segment of NASH patients will provide additional safety information to support the NASH indication and will include key efficacy endpoints: LDL-cholesterol lowering, triglyceride lowering, reduction of liver fat as determined by MRI-PDFF, as well as reduction of elevated liver enzymes and reduction in fibrosis biomarkers. This is a non-biopsy study in people with NASH, as documented using non-invasive techniques or historical liver biopsy.

CareMount Medical

We have a number of positions available in our modern medical offices conveniently located at 90 and 110 South Bedford Road in Mount Kisco, as well as openings in our off-site offices in Yorktown, Katonah, Carmel, Fishkill, Poughkeepsie, Somers, Mahopa...

Semafore Pharmaceuticals

Semafore Pharmaceuticals is a Westfield, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

fusionmed

fusionmed is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharmaceutical Buyers

Pharmaceutical Buyers is a Cedarhurst, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.